CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 106 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q3 2019. The put-call ratio across all filers is 1.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $40,000 | +90.5% | 20,523 | +20.6% | 0.00% | – |
| Q4 2020 | $21,000 | -47.5% | 17,018 | -23.8% | 0.00% | – |
| Q3 2020 | $40,000 | -76.9% | 22,321 | +8.4% | 0.00% | -100.0% |
| Q2 2020 | $173,000 | +158.2% | 20,590 | +62.2% | 0.00% | – |
| Q1 2020 | $67,000 | -44.2% | 12,696 | -42.4% | 0.00% | -100.0% |
| Q4 2019 | $120,000 | +1.7% | 22,031 | -9.2% | 0.00% | 0.0% |
| Q3 2019 | $118,000 | -31.0% | 24,264 | -1.4% | 0.00% | 0.0% |
| Q2 2019 | $171,000 | -9.5% | 24,617 | -9.6% | 0.00% | 0.0% |
| Q1 2019 | $189,000 | +31.2% | 27,226 | +10.4% | 0.00% | 0.0% |
| Q4 2018 | $144,000 | -35.1% | 24,655 | -16.2% | 0.00% | -50.0% |
| Q3 2018 | $222,000 | +44.2% | 29,431 | -3.8% | 0.00% | +100.0% |
| Q2 2018 | $154,000 | -21.0% | 30,585 | -4.4% | 0.00% | 0.0% |
| Q1 2018 | $195,000 | -25.3% | 31,986 | -13.0% | 0.00% | -50.0% |
| Q4 2017 | $261,000 | – | 36,756 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 397,168 | $43,888 | 0.01% |
| CJM Wealth Advisers, Ltd. | 30,465 | $3,366 | 0.00% |
| Tekla Capital Management LLC | 154,310 | $17,051 | 0.00% |
| McAdam, LLC | 10,006 | $6 | 0.00% |
| Aries Wealth Management | 15,400 | $1,702 | 0.00% |
| WELLS FARGO & COMPANY/MN | 342,084 | $37,800 | 0.00% |
| JPMORGAN CHASE & CO | 43,415 | $5 | 0.00% |
| NORTHERN TRUST CORP | 207,329 | $22,910 | 0.00% |
| PINNACLE ASSOCIATES LTD | 18,580 | $2,053 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |